The evidence proving GLP-1s can curb alcohol craving

Person drinking from a dark bottle close-up — Photo: DreamerAchieverNoraTarvus / Shutterstock

A diabetes shot that curbs appetite may also be quieting the urge to drink, smoke, or use drugs.

Quick Take

A small clinical trial found low-dose semaglutide cut alcohol consumption and craving in people with alcohol use disorder.
A massive study of more than 600,000 veterans linked GLP-1 drugs to lower rates of alcohol, opioid, cocaine, nicotine, and cannabis disorders.
Scientists are now running several placebo-controlled trials to test whether the effect is real and how long it lasts.
No GLP-1 drug is approved for addiction treatment, and experts call the current evidence promising but still early.

A Diabetes Drug Shows Up In Addiction Research

Semaglutide and similar GLP-1 drugs built their reputation on weight loss and blood sugar control. Brand names like Ozempic and Wegovy became household words. Now researchers are asking a different question entirely. Can the same drug that shrinks appetite also shrink the pull of alcohol, opioids, or nicotine? Early data says maybe, and that has addiction doctors paying close attention.

The clearest human evidence comes from a randomized trial published in JAMA Psychiatry. Doctors gave 48 adults with alcohol use disorder weekly semaglutide or a placebo for nine weeks. Those on the drug drank less alcohol in a lab test and had lower peak breath alcohol levels than the placebo group. Researchers also reported reduced alcohol cravings, a separate effect from simply drinking less in the moment.

A Massive Veterans Study Adds Weight To The Theory

Beyond the small trial, a much bigger picture emerged from health records of over 600,000 military veterans. Those taking GLP-1 drugs showed notably lower rates of several substance use disorders. Alcohol-related diagnoses dropped 18 percent, cannabis 14 percent, cocaine and nicotine 20 percent each, and opioid disorders fell 25 percent. Washington University researchers who worked on related data called the pattern consistent across multiple addictive substances.

That veterans study is observational, meaning it tracked existing patient records rather than randomly assigning treatment. It cannot prove the drug caused the lower addiction rates on its own. Confounding factors like prescribing patterns, healthcare access, and the group’s makeup, mostly older white men, limit how far the findings can be applied to the general population.

Why Scientists Think The Drug Might Dampen Cravings

GLP-1 drugs were designed to mimic a gut hormone that signals fullness to the brain. Researchers now suspect that same brain pathway touches reward circuits tied to addiction, not just appetite. The National Institutes of Health notes that animal and human findings pushed scientists to launch several randomized trials testing semaglutide specifically for alcohol use disorder. One of those trials, called STAR, is tracking brain connectivity and cue reactivity alongside drinking behavior.

What’s Still Unknown Before Doctors Can Prescribe With Confidence

The 48-person trial is a strong signal, but it is still a small sample studied for just nine weeks. It measured short-term lab drinking, not long-term sobriety, relapse rates, or recovery outcomes. The participants also were not actively seeking treatment, which may not reflect people entering rehab or medication-assisted recovery programs. Bigger, longer studies in treatment-seeking patients are the next necessary step researchers have identified.

No GLP-1 drug currently carries federal approval for treating addiction. That gap matters for everyday patients. Insurance companies often will not cover these costly medications when prescribed off-label for cravings instead of diabetes or obesity, leaving many people who might benefit unable to afford them. Stanford Medicine researchers flag this access barrier as a real-world obstacle separate from whether the science eventually holds up.

The Road Ahead For This Emerging Treatment Idea

Researchers are now pushing for larger, multisite trials that run a full year or longer, comparing GLP-1 drugs against established addiction medications like naltrexone. Other planned studies aim to settle whether brain scans show real changes in reward circuits after treatment, and whether benefits last after patients stop taking the drug. Until those results land, doctors are watching a genuinely promising lead that has not yet become settled medical fact.

What makes this story worth tracking is the convergence of evidence types pointing the same direction. A randomized trial, a massive veterans dataset, and animal research all point toward the same hypothesis independently. That kind of alignment does not happen often in addiction medicine, where promising leads frequently fizzle once tested at scale. Patients and families watching the opioid and alcohol crisis deserve to see where this leads next.

GLP-1 medications are showing real promise for curbing urges and cravings in recovery — but they’re not risk-free.

Drugs like semaglutide (Ozempic/Wegovy) and similar GLP-1 receptor agonists work by acting on brain reward pathways. They dampen the dopamine response to… pic.twitter.com/zuVRHhqykx

— The Sober Soldiers Outreach Foundation (@TheSoberLegion) November 8, 2026

Addiction treatment has not seen a genuinely new pharmacological approach in years, which explains why even cautious researchers sound hopeful. If larger trials confirm what the small studies suggest, GLP-1 drugs could join a short list of medications, alongside naltrexone and varenicline, that actually move the needle on substance use disorders nationwide.